Article
Response to targeted therapy in two patients with metastatic melanoma carrying rare BRAF exon 15 mutations: A598_T599insV and V600_K601delinsE.
Melanoma research - 1 Oct 2017
Rogiers Aljosja, Vander Borght Sara, Tuand Krizia, Wolter Pascal, Stas Marguerite, Boecxstaens Veerle, Garmyn Marjan, van den Oord Joost J, Vandenberghe Peter, Bechter Oliver
Abstract excerpt
Concurrent BRAF-MEK inhibition improves clinical outcomes in patients with advanced BRAF V600E/K-mutant melanoma. There is currently less evidence for the efficacy of this treatment in patients with rare BRAF non-V600E/K genotypes. We report on two patients with rare BRAF exon 15 mutations - BRAF A598_T599insV and V600_K601delinsE - obtaining clinical benefit and a radiological response to inhibitors directed...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.